This web map utilizes an outside feature layer created by Johns Hopkins University.This map is not affiliated with Johns Hopkins University, it's team of researchers or any other persons involved in the creation or maintenance of this source feature layer. Any any all rights to source content are retained by the creators and developers of said content.This web map visually depicts statewide range of COVID-19 cases and deaths (updated daily) with additional hospital capacity data and ACS socioeconomic, age and ethnicity indicators included.Description of original feature layer from source site included below: This feature layer contains the most up-to-date COVID-19 cases for the US. Data is pulled from the Coronavirus COVID-19 Global Cases by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, the Red Cross, the Census American Community Survey, and the Bureau of Labor and Statistics, and aggregated at the US county level. Visit original feature layer page here.Visit the Johns Hopkins University COVID-19 United States Cases by County Dashboard here.We would like to formally thank Johns Hopkins University and it's researchers for all of the work they have contributed to analyzing and fighting the COVID pandemic and for graciously making their work publicly available online and through the ArcGIS platform. We appreciate their efforts more than we can fully express and would like to dedicate this map to them and everyone effected by the pandemic.

Mexico COVID-19 clinical data 🦠🇲🇽

This dataset contains the results of real-time PCR testing for COVID-19 in Mexico as reported by the [General Directorate of Epidemiology](https://www.gob.mx/salud/documentos/datos-abiertos-152127).

The official, raw dataset is available in the Official Secretary of Epidemiology website: https://www.gob.mx/salud/documentos/datos-abiertos-152127.

You might also want to download the official column descriptors and the variable definitions - e.g. SEXO=1 -> Female; SEXO=2 -> Male; SEXO=99 -> Undisclosed) - in the following [zip file](http://datosabiertos.salud.gob.mx/gobmx/salud/datos_abiertos/diccionario_datos_covid19.zip). I've maintained the original levels as described in the official dataset, unless otherwise specified.

IMPORTANT: This dataset has been maintained since the original data releases, which weren't tabular, but rather consisted of PDF files, often with many/different inconsistencies which had to be resolved carefully and is annotated in the .R script. More later datasets should be more reliable, but earlier there were a lot of things to figure out like e.g. when the official methodology to assign the region of the case was changed to be based on residence rather than origin). I've added more notes on very early data here: https://github.com/marianarf/covid19_mexico_data.

Coronavirus-19 Cases vs. Deaths (Hourly Update)See Detailed graphs and tables describing the COVID-19 crisis in New Mexico, updated daily (includes some county level data not found elsewhere) - https://sites.google.com/view/new-mexico-covid19-tracking/homeCDC's Description of the Social Vulnerability Index (takes into account 15 different selected indicators):https://svi.cdc.gov/

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status. Click 'More' for important dataset description and footnotes

Dataset and data visualization details: These data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022.

Vaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. Additional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type. ** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group. Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis. Participating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases

Note: Authorizations to collect certain public health data expired at the end of the U.S. public health emergency declaration on May 11, 2023. The following jurisdictions discontinued COVID-19 case notifications to CDC: Iowa (11/8/21), Kansas (5/12/23), Louisiana (10/31/23), New Hampshire (5/23/23), and Oklahoma (5/2/23). Please note that these jurisdictions will not routinely send new case data after the dates indicated. As of 7/13/23, case notifications from Oregon will only include pediatric cases resulting in death.

This table summarizes COVID-19 case and death data submitted to CDC as case reports for the line-level dataset. Case and death counts are stratified according to sex, age, and race and ethnicity at regional and national levels. Data for US territories are included in case and death counts, but not population counts. Weekly cumulative counts with five or fewer cases or deaths are not reported to protect confidentiality of patients. Records with unknown or missing sex, age, or race and ethnicity and of multiple, non-Hispanic race and ethnicity are included in case and death totals. COVID-19 case and death data are provisional and are subject to change. Visualization of COVID-19 case and death rate trends by demographic variables may be viewed on COVID Data Tracker (https://covid.cdc.gov/covid-data-tracker/#demographicsovertime).

Deaths involving coronavirus disease 2019 (COVID-19) reported to NCHS by time-period, HHS region, race and Hispanic origin, and age groups (<65, 65-74. 75-84, 85+, and 65+). United States death counts include the 50 states, plus the District of Columbia and New York City. The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York, New York City; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington.

This file contains COVID-19 death counts and rates by month and year of death, jurisdiction of residence (U.S., HHS Region) and demographic characteristics (sex, age, race and Hispanic origin, and age/race and Hispanic origin). United States death counts and rates include the 50 states, plus the District of Columbia. Deaths with confirmed or presumed COVID-19, coded to ICD–10 code U07.1. Number of deaths reported in this file are the total number of COVID-19 deaths received and coded as of the date of analysis and may not represent all deaths that occurred in that period. Counts of deaths occurring before or after the reporting period are not included in the file. Data during recent periods are incomplete because of the lag in time between when the death occurred and when the death certificate is completed, submitted to NCHS and processed for reporting purposes. This delay can range from 1 week to 8 weeks or more, depending on the jurisdiction and cause of death. Death counts should not be compared across jurisdictions. Data timeliness varies by state. Some states report deaths on a daily basis, while other states report deaths weekly or monthly. The ten (10) United States Department of Health and Human Services (HHS) regions include the following jurisdictions. Region 1: Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont; Region 2: New Jersey, New York; Region 3: Delaware, District of Columbia, Maryland, Pennsylvania, Virginia, West Virginia; Region 4: Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee; Region 5: Illinois, Indiana, Michigan, Minnesota, Ohio, Wisconsin; Region 6: Arkansas, Louisiana, New Mexico, Oklahoma, Texas; Region 7: Iowa, Kansas, Missouri, Nebraska; Region 8: Colorado, Montana, North Dakota, South Dakota, Utah, Wyoming; Region 9: Arizona, California, Hawaii, Nevada; Region 10: Alaska, Idaho, Oregon, Washington. Rates were calculated using the population estimates for 2021, which are estimated as of July 1, 2021 based on the Blended Base produced by the US Census Bureau in lieu of the April 1, 2020 decennial population count. The Blended Base consists of the blend of Vintage 2020 postcensal population estimates, 2020 Demographic Analysis Estimates, and 2020 Census PL 94-171 Redistricting File (see https://www2.census.gov/programs-surveys/popest/technical-documentation/methodology/2020-2021/methods-statement-v2021.pdf). Rate are based on deaths occurring in the specified week and are age-adjusted to the 2000 standard population using the direct method (see https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-08-508.pdf). These rates differ from annual age-adjusted rates, typically presented in NCHS publications based on a full year of data and annualized weekly age-adjusted rates which have been adjusted to allow comparison with annual rates. Annualization rates presents deaths per year per 100,000 population that would be expected in a year if the observed period specific (weekly) rate prevailed for a full year. Sub-national death counts between 1-9 are suppressed in accordance with NCHS data confidentiality standards. Rates based on death counts less than 20 are suppressed in accordance with NCHS standards of reliability as specified in NCHS Data Presentation Standards for Proportions (available from: https://www.cdc.gov/nchs/data/series/sr_02/sr02_175.pdf.).

Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Updated (Bivalent) Booster Status. Click 'More' for important dataset description and footnotes

Webpage: https://covid.cdc.gov/covid-data-tracker/#rates-by-vaccine-status

Dataset and data visualization details:

These data were posted and archived on May 30, 2023 and reflect cases among persons with a positive specimen collection date through April 22, 2023, and deaths among persons with a positive specimen collection date through April 1, 2023. These data will no longer be updated after May 2023.

Vaccination status: A person vaccinated with at least a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected. A person vaccinated with a primary series and a monovalent booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and at least one additional dose of any monovalent FDA-authorized or approved COVID-19 vaccine on or after August 13, 2021. (Note: this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose.) A person vaccinated with a primary series and an updated (bivalent) booster dose had SARS-CoV-2 RNA or antigen detected in a respiratory specimen collected ≥14 days after verifiably receiving a primary series of an FDA-authorized or approved vaccine and an additional dose of any bivalent FDA-authorized or approved vaccine COVID-19 vaccine on or after September 1, 2022. (Note: Doses with bivalent doses reported as first or second doses are classified as vaccinated with a bivalent booster dose.) People with primary series or a monovalent booster dose were combined in the “vaccinated without an updated booster” category.

Deaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Per the interim guidance of the Council of State and Territorial Epidemiologists (CSTE), this should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as the underlying cause of death or as a significant condition contributing to death. Rates of COVID-19 deaths by vaccination status are primarily reported based on when the patient was tested for COVID-19. In select jurisdictions, deaths are included that are not laboratory confirmed and are reported based on alternative dates (i.e., onset date for most; or date of death or report date, where onset date is unavailable). Deaths usually occur up to 30 days after COVID-19 diagnosis.

Participating jurisdictions: Currently, these 24 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Colorado, District of Columbia, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (NY), North Carolina, Rhode Island, Tennessee, Texas, Utah, and West Virginia; 23 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 48% of the total U.S. population and all ten of the Health and Human Services Regions. This list will be

Data across all counties in five states (Arizona, Colorado, New Mexico, Oklahoma, and Texas) in the U.S. were collected for the study on the impact of the socio-economic and political status on the county-level COVID-19 vaccination rates. Variables were obtained from various data sources; the Bureau of Labor Statistics, Bureau of Economic Analysis, 2010 US Census, Politico, and Centers for Disease Control and Prevention (CDC). It was found that county-level vaccination rates were significantly associated with the percentage of Democrat votes, the elderly population, and per capita income of the county. In addition, the results revealed racial and ethnic disparities in COVID-19 vaccination. The manuscript entitled “Socio-political and Economic Impact on the COVID-19 Vaccination: Southwest Regional Study” was submitted for publication.

See another Navajo Nation COVID19 map at the Navajo Epidemiology Center: https://navajo-nation-coronavirus-response-ndoh-nec.hub.arcgis.com/

Data-set of the paper Disentangling Covid-19, Economic Mobility, and Containment Policy Shocks for replication purpose of the Data Editor of AEJMacro. Detailed information on the data-set is in the readme file in the public repository openicpsr-175241 (under review).

We study the dynamic interaction between Covid-19, economic mobility, and containment policy. We use Bayesian panel structural vector autoregressions with daily data for 44 countries, identified through traditional and narrative sign restrictions. We find that incidence shocks and containment shocks have large and persistent effects on mobility, morbidity, and mortality that last for 1-2 months. These shocks are the main drivers of the pandemic, explaining between 20-60% of the average and historical variability in mobility, cases, and deaths worldwide. The policy tradeoff associated to non-pharmaceutical interventions is 1pp less economic mobility per day for 8% fewer deaths after three months.

The panel data-set contains the main data to perform the analysis in the paper. It contains dailiy data for (in sheets) Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hong Kong, Hungary, India, Indonesia, Ireland, Israel, Italy, Japan, Lithuania, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Russia, Saudi Arabia, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Arab Emirates, United Kingdom and United States. Included variables are: Confirmed Cases, Total Deaths, Days Last Reported Case, Total Tests, School Closing, Workplace Closing, Cancel Public Events, Restrictions Gatherings, Close Public Transport, Stay at Home Requirements, Restrictions Internal Movement, International Travel Controls, Income Support, Debt/Contract Relief, Fiscal Measures, International Support, Public Information Campaigns, Testing Policy, Contact Tracing, Healthcare Emergency Investment, Investment Vaccines, Stringency Index, Small Cap, Large Cap, Government Benchmarks 3 Month, Government Benchmarks 1 Year, Government Benchmarks 2 Year, Government Benchmarks 5 Year, Government Benchmarks 10 Year, FX Indices Broad, FX Indices Narrow, Mobility Retail Mobility Grocery, Mobility Parks, Mobility Transit Stations Mobility Workplaces, Mobility Residential. Period: 30.12.2016 to 31.08.2020. All data are downloaded from Macrobond.

Boroughs of Mexico City.

Mean number of trips from zones 1-16 to zones 1-9 during a day of the weekend.

Parameter estimation of βs, βa, ρ, α, γ, θ and initial conditions of the model (1).